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 Sialyl Lewisa (CA19-9) and sialyl LewisX antigens 
(CSLEXI) may play a role in tumor metastasis by serving 
as functional ligands in the cell adhesion system. To deter-
mine their prognostic value, we examined preoperative 
serum levels of CA19-9, CSLEXI, and carcinoembryonic an-
tigen (CEA) in 64 female patients with primary breast can-
cer who underwent radical mastectomy. The patients were 
divided into two groups, termed the low- and high-antigen 
groups based on a value selected as a diagnostic cut-off. 
Correlation between the serum antigen levels, various es-
tablished clinicopathologic factors, and prognosis were 
studied by univariate and multivariate analysis. The high-
CEA group was at a more advanced stage (including T fac-
tor, N factor, M factor, and Stage) than the low-CEA group. 
Patients with high serum levels of CEA had shorter dis-
ease-specific intervals than those with low serum levels (P 
<0.0001), whereas disease-specific intervals did not differ 
between low- and high-CA19-9 or CSLEXI groups. A Cox's 
regression multivariate analysis revealed a high serum 
CEA level as an independent factor for worse outcome, 
separate from Stage. In conclusion, an elevated preopera-
tive serum CEA level was a predictor for poor outcome 
after radical mastectomy for breast cancer, while CA19-9 
and CSLEX1 were not. 
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Introduction
 The composition of cell surface carbohydrates usu-
ally changes with tumor development.' > Among the 
tumor-associated carbohydrate molecules that accumu-
late substantially in solid tumors, sialyl Lewisa and 
sialyl LewisX antigens are representative examples of 
type 1 and type 2 terminal structures, respectively."" 
Several studies indicate that tumor cells expressing 
sialyl Lewisa and/or sialyl Lewisx antigens adhere to 
cultured endothelial cells activated by certain 
interleukins. 3 - 5' This observation supports the idea 
that sialyl Lewisa and/or sialyl Lewisx antigens may 
actually play a role in the adhesion of cancer cells to 
endothelial cells, resulting in hematogenous metastasis. 
Sialyl Lewisa and/or sialyl LewisX antigens accumu-
late in breast cancer tissues.'-" In addition, increased 
expression of sialyl LewisX antigen, as demonstrated 
by immunohistochemistry, has been shown to corre-
late with poor prognoses in breast cancer patients 
after surgery." > Although circulating sialyl Lewisa 
and/or sialyl LewisX antigens are also detected in the 
blood streams of breast cancer patients, their prognos-
tic value in breast cancer patients has not been exten-
sively discussed.""' 
 In this study, we examined the preoperative serum 
levels of sialyl Lewisa and sialyl LewisX antigens in 
breast cancer patients in order to clarify the role of 
these two carbohydrate antigens as prognostic factors 
after radical mastectomy. We also evaluated CEA lev-
els in the same patients because CEA has been consid-
ered as one of the most useful tumor markers for a 
wide variety of malignancies, including breast carci-
noma. 1-15) The prognostic values of sialyl Lewisa, 
sialyl LewisX antigens, and CEA were compared.
Patients and Methods
Patients
  Sixty-four female patients with primary breast cancers 
who underwent either Halsted or modified radical 
mastectomy at Nagasaki University Hospital and Sasebo 
Municipal Hospital between April 1985 and December 
1986 were enrolled in this study. All patients had 
locoregional or systemic untreated breast cancer. 
Patients who had a synchronous or metachronous can-
cer of the breast, or evidence of other organ malignan-
cies, were excluded from this study. We prospectively 
evaluated the prognostic values of sialyl Lewisa, sialyl 
Lewisx antigens, and CEA in the patients. 
 The recommendations of the American Joint Committee 
on Cancer Classification and Stage grouping were 
used to classify the tumors."' Each tumor was 
histopathologically classified according to its histology 
as a papillo-tubular, solid-tubular, scirrhous, or mucinous 
carcinoma, using the General Rules for Clinical and 
Pathological Recording of Breast Cancer presented by 
the Japanese Breast Cancer Society."' 
 Patients with stage II-IV tumors received adjuvant 
cytotoxic chemotherapy (oral administration of 5-
fluorouracil (5-FU) or 5-FU analogues) after surgery, 
while patients with stage I tumors did not. Data from 
patients who died of causes other than breast cancer 
were censored in the survival analysis. No patient 
died within 30 postoperative days. Written informed 
consent was obtained from each patient.
Measurement of serum antigen levels
 In order to detect the presence of circulating cancer 
markers, venous blood was obtained after an over-
night fast. The blood samples were separated immedi-
ately by centrifugation, and the remaining blood sera 
were stored at -80'C until use. The serum levels of 
sialyl Lewisa antigen (CA 19-9) and CEA were measured 
in the Otsuka Assay Laboratory (Tokushima, Japan) 
using commercially available radioimmunoassay kits: 
specifically, Centocor CA19-9 RIA kit (Centocor, 
Malvern, PA, USA)18) and CEA Roche 2 (Nippon 
Roche K.K., Tokyo, Japan)19', respectively. The serum 
levels of sialyl Lewisx antigen (CSLEX 1) were meas-
ured using the fluorescent enzyme immunoassay we 
described previously20'. The data obtained were based 
on the simultaneous assay for these three antigens 
using the same set of sera. 
 The cut-off values recommended by the manufactur-
ers for diagnostic use are 37 U/ml for CA19-918' and 
2.5 ng/ml for CEA19', while 149 U/ml for CSLEXI was
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reported previously"'. For each antigen, we classified 
the patients into two groups: a high-antigen group, 
with serum antigen concentrations greater than the 
selected cut-off value, and a low-antigen group, with 
concentrations less than the cut-off value.
Statistical analysis
 Statistical analyses were performed using the com-
puter program STATISTICATM (StatSoft, Tulsa, 
Oklahoma, USA). A variable, age, was classified into 
two groups based on its median (53.0 years). The X 2 
test or Fisher's exact test was performed to assess as-
sociation levels between expected and detected fre-
quency. In evaluating the prognostic value of CA 19-9, 
CSLEXI, and CEA, the disease-specific intervals 
served as the study endpoint. The influence of each 
variable on the disease-specific interval was calculated 
according to the Kaplan-Meier method,"' and differ-
ences between disease-specific intervals were tested 
for significance using the log rank test."' The prog-
nostic relevance of a single factor was determined by 
the application of the univariate Cox's regression 
analysis, whereas antigen status and well-established 
factors (pathologic stage of disease after primary ther-
apy and histologic type)") were analyzed by using 
multivariate Cox' regression analysis"'. All tests were 
two-tailed and a P value of less than 0.05 was consid-
ered significant.
Results
Comparison of clinicopathologic features between the 
low- and high-antigen groups
 Among the 64 patients, high levels of each antigen 
were observed as follows: CA 19-9 in 7 patients (10.9%), 
CSLEX1 in 19 (29.7%), and CEA in 12 (18.8%). 
 There was a statistically significant difference in the 
proportion of histologic types when comparing low-
and high-CA 19-9 groups. There was a statistically sig-
nificant difference in the proportion of age and meno-
pausal status between low- and high-CEA groups. The 
high-CEA group was at a more advanced stage (in-
cluding T factor, N factor, M factor, and pathological 
Stage) than the low-CEA group. However, there were 
no differences in the other variables compared between 
any of the low- and high-antigen groups (Table 1). 
 The number of patients with high antigen levels 
who underwent Halsted or modified radical mastec-
tomy was as follows: 4 (22.2%) or 3 (6.5%) for CA19-9, 
6 (33.3%) or 13 (28.3%) for CSLEXI, and 4 (22.2%) or 8
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(17.4%) for CEA, respectively (P=0.090, P=0.56, and P 
=0.73, respectively). Thus, there was no difference be-
tween groups with regard to operative procedure per-
formed.
did not differ between low and high CEA antigen 
groups. In addition, no patients with stage I tumors 
had died of breast cancer during the 130 months 
follow-up (Fig. 2).
Table 1. Comparison of clinicopathological features of tumors 
with frequency of patients in high-antigen group.
                                                  No. in high-antigen group (%) 
Variables CA19-9 antigen CSLEXI CEA 
                           (n=7) P value* (n=19) P value* (n=12) P value* 
Age (years) 0.43 0.27 0.022 
  <53 (n=32) 2(6.3) 12 (37.5) 2(6.3) 
  <53 (n=32) 5(15.6) 7(21.9) 10 (31.3) 
Menopausal status 0.24 0.76 0.0057 
  Premenopausal (n=34) 2(5.9) 12 (35.3) 2(5.9) 
  Postmenopausal (n=30) 5(16.7) 7(23.3) 10 (33.3) 
Histology 0.019 0.14 0.17 
  Papillo-tubular (n=8) 0(0) 0(0) 0(0) 
  Solid-tubular (n=44) 3(6.8) 15 (34.1) 8(18.2) 
  Scirrhous/Mutinous (n=12) 4(33.3) 4(33.3) 4(33.3) 
T 0.046 0.11 0.0068 
  TI (n=26) 3(11.5) 4(15.4) 2(7.7) 
  T2 (n=26) 1(3.8) 10 (38.5) 4(15.4) 
  T3/T4 (n=12) 3(25.0) 5(41.7) 6(50.0) 
N 0.67 0.41 0.0059 
  NO (n=44) 4(9.1) 12 (27.3) 4(9.1) 
  Nl/N2 (n=20) 3(15.0) 7(35.0) 8(40.0) 
M 0.21 0.51 0.033 
  MO (n=62) 6(9.7) 18 (29.0) 10 (16.1) 
  MI (n=2) 1(50.0) 1(50.0) 2(100) 
Stage 0.062 0.096 0.0012 
  
I (n=20) 3(15.0) 2(10.0) 2(10.0) 
  II (n=34) 1(2.9) 14 (41.2) 4(11.8) 
  III (n=8) 2(25.0)) 2(25.0) 4(50.0) 
  IV (n=2) 1(50.0) 1(50.0) 2(100) 
* P value based on the XS test or Fisher's exact test.
Comparison of disease-specific interval after surgery be-
tween low- and high-antigen groups 
 At the time these data were analyzed, the median 
follow-up was 58.3 (range: 10.4-138.7) months. Of the 
64 patients, 48 were alive and 2 patients had died of 
other causes, while 14 had died of breast cancer (some 
patients had more than one cause of death): 6 with 
local recurrence, 6 with bone metastasis, 2 with lung 
metastasis, and 1 with liver metastasis. 
 Patients with high serum levels of CEA had shorter 
disease-specific intervals than those with low serum 
levels (P<0.0001), whereas disease-specific intervals did 
not differ between low and high CA 19-9 or CSLEX 1 
groups (Fig. 1). 
 Patients with stage II tumors who had high serum 
CEA levels had shorter disease-specific intervals than 
those with low serum levels. In contrast, the disease-
specific interval of patients with stage III/IV tumors
Figure 1. Comparison of disease-specific intervals between 
low- and high-antigen groups. 
after resection for breast cancer
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Cox's regression analysis for the prognostic value of 
serum antigen levels 
 To avoid the problem of co-linearity, variables such 
as menopausal status, T factor, N factor, and M factor, 
were excluded. The 6 remaining variables (age, histol-
ogy, stage, serum CA 19-9 status, serum CSLEX 1 
status, serum CEA status) were included in this analy-
sis. According to an univariate Cox's regression analy-
sis, stage and serum CEA status were associated with 
poor disease-specific survival (Table 2). To determine 
the independent prognostic value of the serum antigen, 
multivariate analysis was performed. Consequently, 
two independent variables, stage and serum CEA 
status, were found to be significant for predicting dis-
ease-specific survival (Table 2).
Discussion
Figure 2. Disease-specific intervals of patients with stage I, 
stage II, or stage III/IV breast cancer, and with high or low 
antigen levels after radical mastectomy.
Table 2. Prognostic variables for survival in Cox's regression 
analysis.
                          Univariate analysis Multivariate analysis 
Variables HR (95% CI)* P value HR (95% Cl)* P value 
Age at diagnosis (years) 
  <53 (n=32) 1 1 
  z53 (n=32) 2.31 (0.72-7.38) 0.16 0.72 (0.09-5.59) 0.75 
Histology 
  Papillo-tubular/Solid-tubular 1 1 
  Scirrhous/Mucinous 2.38 (0.74-7.63) 0.14 1.90 (0.30-12.24) 0.50 
Stage 
  1/11 1 1 
  III/IV 12.17 (4.17-35.56) <0.0001 14.11 (2.90-68.53) 0.0010 
Serum CAI 9-9 status 
  Low group 1 1 
  High group 3.15 (0.87-11.33) 0.079 1.86 (0.11-30.77) 0.67 
Serum CSLEXI status 
  Low group 1 1 
  High group 1.15 (0.31-4.24) 0.83 0.71 (0.05-10.80) 0.80 
Serum CEA status 
  Low group 1 1 
  High group 12.16 (3.79-39.02) <0.0001 8.43 (2.11-33.71) 0.0026 
*HR, hazard ratio; Cl, confidence interval.
 Current therapeutic strategies for individual patients 
with primary breast cancer frequently are determined 
by the following variables: (1) the size (T factor) of 
the primary tumor; (2) the presence and extent of 
axillary lymph node metastases (N factor); (3) patho-
logic stage of the disease after primary therapy; and 
(4) the presence or absence of estrogen receptor and 
progesterone receptor activity. 16, 24) It would be of great 
value to have an easily performed blood test that re-
liably predicts prognosis, independent of TMN stage.") 
For this reason, many circulating tumor markers, such 
as carcinoembryonic antigen (CEA)11-15) CA 15-311, 13, 15.26)' 
E-selecting), c-erbB-215), and CYFRA 21-127), have been 
investigated for use in breast cancer patients. 
However, there are few known circulating tumor 
markers with established clinical utility.25) 
 In the current study, multivariate Cox's regression 
analysis revealed that a high preoperative serum CEA 
level was an independent prognostic factor for dis-
ease-specific survival after radical mastectomy for 
breast cancer, whereas circulating CA 19-9 or CSLEX 1 
did not correlate with disease-specific survival. 
 The prognostic value of the preoperative serum 
CA 19-9 level in patients with gastric and colorectal 
cancer has been reported .21-") For example, Filella et 
al.") reported the prognostic value of circulating 
CA 19-9 based on the disease-free interval after cura-
tive surgery in 162 colorectal cancer patients, and 
noted that CA 19-9 provides more prognostic informa-
tion than conventional staging methods (Dukes' classi-
fication). In contrast, the current study did not reveal 
the prognostic value of circulating CA 19-9 in breast 
cancer patients. Narita et al.') also reported that sialyl
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Lewisa antigen expression in tumor tissue, as demon-
strated by immunohistochemistry, did not correlate 
with overall survival or relapse-free survival in 300 
breast cancer patients. Based on these findings, we be-
lieve that circulating sialyl Lewisa antigen may have 
no prognostic value in breast cancer patients. 
 Narita et al." also reported that increased expres-
sion of sialyl Lewisx antigen in tumor tissue, as dem-
onstrated by immunohistochemistry, correlated with a 
poor prognosis in breast cancer patients who under-
went mastectomy. Matuura et al." reported that in-
creased serum levels of sialyl Lewisx antigen are ob-
served in patients with advanced and recurrent breast 
cancer, especially in those with distant metastasis. 
However, the current study showed no correlation be-
tween serum levels of sialyl Lewisx antigen and tumor 
stage or survival after surgery. To date, a prognostic 
value of circulating sialyl Lewisx antigen for survival 
in breast cancer patients has not been reported. 
Further investigation in a large number of patients is 
necessary to clarify this issue. 
 Several studies have reported that preoperative high 
serum levels of CEA correlate with a poor prognosis in 
breast cancer patients who underwent mastectomy. 13-15) 
In addition, preoperative serum CEA levels were 
shown to be an independent prognostic factor, sepa-
rate from stage, by multivariate Cox's regression 
analysis.",") The current study also confirmed the 
prognostic value for survival after surgery. Although 
Nakata et al.") reported no correlation between serum 
CEA levels and prognosis in breast cancer patients, 
this study is different from ours because it included 
patients with both primary and recurrent breast can-
cers. Therefore, we believe that a preoperative high 
serum CEA level is a useful predictor for a poor prog-
nosis in patients with primary breast cancer who un-
dergo radical mastectomy as a first-line therapy.
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